{"schema_version":"secwatch.filing_event.v1","accession":"0001321732-25-000108","form_type":"8-K","ticker":"PEN","cik":"0001321732","company_name":"Penumbra Inc","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.083826+00:00","generated_at":"2026-05-17T00:12:39.270202+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Penumbra Q3 revenue $354.7M (+17.8% YoY); full-year guidance raised to $1.375-1.380B","bullets":["Net income of $45.9M; adjusted EBITDA $66.7M (18.8% margin).","U.S. Thrombectomy revenue $192.0M (+18.5%); U.S. VTE revenue up 34% YoY.","Gross margin improved to 67.8% vs 66.5% a year ago; operating margin 13.8%.","Full-year 2025 revenue guidance increased to $1.375B-$1.380B (15-16% growth).","Total revenue $354.7M (+17.8% or +16.9% constant currency); U.S. revenue +21.5%."],"urls":{"canonical":"https://secwatch.observer/filing/0001321732-25-000108","json":"https://secwatch.observer/filing/0001321732-25-000108.json","markdown":"https://secwatch.observer/filing/0001321732-25-000108.md","text":"https://secwatch.observer/filing/0001321732-25-000108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1321732/000132173225000108/0001321732-25-000108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1321732/000132173225000108/pen-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:12:39.270202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}